EXOMIND vs TMS: BrainsWay Deep TMS Compared
EXOMIND vs TMS is the wrong distinction. EXOMIND is a TMS system. The decision is between BTL's short-protocol ExoTMS approach and BrainsWay's established Deep TMS platform.
The session-count gap gets attention for a reason. EXOMIND is FDA-cleared for depression in just 6 sessions versus 20-30 sessions for BrainsWay Source. That changes scheduling, patient commitment, and how quickly a practice can move a patient through treatment.
Machine price narrows the gap. Both systems list at $100,000-$200,000 new, with BrainsWay used units at $50,000-$120,000 and EXOMIND having a limited secondary market Source.
BrainsWay has the longer clinical track record. EXOMIND has the sharper workflow pitch. Neither advantage is decorative when you are choosing equipment that will sit at the center of a psychiatric service line.
Is EXOMIND Different From TMS? ExoTMS vs Standard rTMS
EXOMIND is not outside the TMS category. It is BTL Industries' TMS platform, using ExoTMS, a patented external TMS approach with a proprietary coil design. Standard rTMS commonly uses figure-eight coils. BrainsWay takes a separate route with Deep TMS and its H-Coil technology.
The hardware distinction affects how a clinician thinks about treatment delivery. BrainsWay's H-coil reaches 6cm of stimulation depth versus 2cm for standard figure-8 coils Source. BrainsWay positions that depth as the defining advantage of its platform.
EXOMIND's case is more operational. The system is built around a short FDA-cleared depression protocol. A practice evaluating it is likely asking whether a much shorter patient journey can create a better fit for its referral base, staffing model, and room capacity.
BrainsWay's helmet design also changes the day-to-day setup. The patient wears the coil assembly rather than requiring the same manual positioning approach associated with many conventional systems. That can make the platform appealing to practices that want a repeatable treatment workflow across staff members.
The comparison is not "TMS versus EXOMIND." It is one type of TMS system against another. ExoTMS emphasizes a compressed protocol. Deep TMS emphasizes stimulation depth, an established platform, and a treatment model many psychiatric practices already understand.
Both are FDA cleared and actively sold in the United States. BrainsWay was FDA cleared in 2013 and EXOMIND in 2024 Source. That clearance gap is part of the buying decision, because it maps closely to the difference in clinical history and secondary-market availability.
Side-by-Side Comparison
| Category | BrainsWay Deep TMS | EXOMIND |
|---|
| New machine price | $100,000-$200,000 | $100,000-$200,000 |
| Used machine price | $50,000-$120,000 | Limited secondary market |
| Depression protocol | 20-30 sessions | 6 sessions |
| FDA clearance year | 2013 | 2024 |
| Evidence maturity | Multiple RCTs for depression and OCD | Emerging peer-reviewed evidence base |
| Per-session economics | $300-$500, insurance reimbursable | TBD |
| Maintenance | $5,000-$10,000 annually | n/a |
The table makes the real tradeoff fairly plain. BrainsWay gives a buyer a more mature commercial and clinical package. EXOMIND offers a shorter treatment protocol, but many of the practice-level questions around utilization and per-session economics are still being worked out.
For a closer look at the established platform, see our BrainsWay Deep TMS review. For the newer entrant's device profile, see our EXOMIND review.
What EXOMIND and BrainsWay Machines Cost
Both systems list at $100,000-$200,000 new, with BrainsWay used units at $50,000-$120,000 and EXOMIND having a limited secondary market Source.
That is the direct answer on machine cost. The more useful answer is that a BrainsWay buyer has another purchasing path. A used market exists because the platform has been deployed for longer. That gives some practices an entry point below a new-machine purchase, though the condition, service arrangement, and remaining useful life of a used unit still deserve scrutiny.
EXOMIND does not offer that same used-market option in a meaningful way yet. It is too new. Buyers should assume a new-device purchase unless a specific opportunity appears and can be properly vetted.
The machine invoice is only part of the capital decision. BrainsWay annual maintenance runs $5,000-$10,000 Source. A practice should build that cost into its financial model rather than treating it as an afterthought after installation.
On the revenue side, BrainsWay per-session pricing runs $300-$500 (insurance reimbursable) Source. Its treatment model is familiar to many referral sources, payers, and practices already operating in the category.
EXOMIND's per-session economics remain TBD. That does not make the system a bad purchase. It means the buyer has to do more of the work themselves. Ask how the short protocol affects patient acquisition, completion, staffing, room usage, clinical oversight, and cash collection. The shorter course may create attractive capacity math. It may also require a different conversation with patients and referral partners who are accustomed to conventional TMS treatment schedules.
Read the BrainsWay Deep TMS cost guide before building a purchase model. The price of the device matters. The cost of operating the service line decides whether the purchase earns its keep.
EXOMIND as a BrainsWay Alternative
EXOMIND belongs on a BrainsWay-alternative shortlist for practices that see the long treatment course as their main constraint.
A psychiatrist with limited room capacity may look at a short protocol and see a way to serve more appropriate patients without expanding the physical footprint. A patient who cannot reliably attend repeated appointments may find the shorter course easier to consider. A practice starting from zero may also prefer a device whose commercial story is simple: fewer visits for the cleared depression protocol.
BrainsWay wins a different buyer. It is a stronger fit for a practice that wants a platform with a longer clinical record, multiple RCTs for depression and OCD, and a smoking cessation indication. It also fits buyers who value a used-market option, established treatment workflows, and a device category that referring clinicians have seen for years.
The choice should not turn on novelty. New equipment always attracts attention. The question is whether the short protocol solves a real bottleneck in your practice.
If most suitable patients can complete a conventional treatment schedule and your referral network already understands Deep TMS, BrainsWay's maturity may carry more weight. If missed appointments and treatment burden regularly kill otherwise appropriate cases, EXOMIND has a cleaner answer.
There is another consideration: adoption risk. A new protocol can require more education for staff, referral partners, and patients. That work may be worth doing. It should be included in the purchase decision, not handed to the front desk after delivery.
The broader TMS and neuromodulation category is useful for comparing where each platform sits alongside other treatment options. Equipment selection is never only about the device. It is about the patient population and operating model that device makes possible.
Clinical Evidence: Established RCTs vs Emerging Data
BrainsWay's evidence base is established. The company has multiple RCTs for depression and OCD, along with a smoking cessation indication. That history gives psychiatrists a more familiar clinical foundation when discussing the treatment with patients, colleagues, and referral sources.
EXOMIND's evidence is emerging. Its full peer-reviewed evidence base is still developing. FDA clearance gives the system a legitimate place in the market, but clearance and evidence maturity are different questions.
That distinction matters most when a practice expects evidence review to be part of the sale. Some clinics have a patient base that wants a concise explanation and a practical treatment path. Others work with highly involved referrers, health systems, or medically complex populations where the depth and breadth of published evidence carry more weight.
BrainsWay's H-Coil technology also gives the platform a clear clinical narrative. BrainsWay's H-coil reaches 6cm of stimulation depth versus 2cm for standard figure-8 coils Source. A buyer can decide how much that distinction matters for their clinical philosophy, but the platform's argument is concrete.
EXOMIND's argument is concrete too. It is built around treatment-course compression. EXOMIND is FDA-cleared for depression in just 6 sessions versus 20-30 sessions for BrainsWay Source. The commercial appeal is obvious, but a practice should still ask how that protocol fits its own standards for patient selection, informed consent, outcome tracking, and follow-up.
Evidence maturity is where BrainsWay has the stronger hand today. Workflow innovation is where EXOMIND has the sharper pitch. A buyer who treats those as interchangeable will end up comparing brochure language instead of making a clinical and operational decision.
Workflow, Staffing, and Patient Experience
BrainsWay sessions run 20 minutes each Source. Combined with a longer course, that creates a familiar scheduling rhythm for an established TMS practice.
EXOMIND's short course changes that rhythm. Fewer appointments can reduce the burden on a patient who has transportation, work, family, or distance constraints. It can also change how a practice manages intake and follow-up. Faster patient turnover sounds attractive until you remember that intake, clinical assessment, documentation, and referral management do not disappear.
The shorter protocol may be a better fit for a practice with strong demand but limited appointment availability. It may be less meaningful for a clinic where the main constraint is referral volume, clinician time, or reimbursement complexity.
BrainsWay's longer course can create more touchpoints with patients. That can support monitoring and relationship-building, though it also demands more attendance. EXOMIND compresses the commitment. The clinic has to decide whether that is more likely to improve completion or concentrate the same operational work into a shorter window.
Ask device vendors to walk through the patient journey from referral through follow-up. Ask them to separate what the machine does from what your staff still has to do. The sales presentation should survive that conversation.
A practice should buy EXOMIND when the short protocol solves a concrete access or capacity problem. It should buy BrainsWay when the established evidence base, deep-stimulation approach, broader commercial maturity, and used-market availability outweigh the appeal of a compressed treatment course.
The hard part is admitting which problem you are trying to solve. A device cannot fix a weak referral engine. It can change the economics and patient experience once the right patients are arriving.
Established Platform vs Newcomer
BrainsWay has been FDA-cleared for depression since 2013 and has the deepest clinical evidence base of any deep TMS system. EXOMIND is BTL's entry into neuromodulation, built on their ExoTMS coil design. The fundamental trade-off is proven clinical history versus a dramatically shorter treatment protocol.
BrainsWay's 20-36 session protocol is the industry standard. EXOMIND's 6-session protocol, if it holds up to broader clinical use, could transform the economics of TMS by tripling patient throughput per chair. However, 6-session protocols have less long-term durability data. Practices considering EXOMIND should ask BTL for their maintenance session recommendations and long-term follow-up data.
BTL Ecosystem Advantage
If your practice already uses BTL devices (Emsella, Emsculpt Neo), EXOMIND integrates into the same service and training infrastructure. BTL's sales team is aggressive and often bundles EXOMIND pricing with aesthetic device packages. This bundling can reduce the effective capital cost substantially. BrainsWay does not offer cross-category bundling because TMS is their only product line.